{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:34:27Z","timestamp":1789389267313,"version":"build-2803163510"},"reference-count":35,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Polatuzumab vedotin (PoV) is a novel antibody-drug conjugate that targets CD79B for the treatment of Non-Hodgkin Lymphoma (NHL). This meta-analysis aimed to evaluate the efficacy and safety of PoV in patients with NHL. A systematic review and meta-analysis of clinical trials evaluating PoV in NHL were conducted. The primary outcomes were complete response (CR) rates, progression-free survival (PFS), and overall survival (OS). Safety outcomes were also assessed. Random-effects models were used for the pooled analyses. Thirteen studies with 1533 patients with NHL were included. PoV significantly improved CR rates compared to control treatments (OR 1.50, 95% CI 1.01\u20132.21, p = 0.04) and PFS (MD 4.17 months, 95% CI 2.18\u20136.15, p &lt; 0.0001). OS was not significantly different (OR 0.97, 95% CI 0.47\u20132.01, p = 0.93). Adverse events were more common with PoV (RR 1.38, 95% CI 0.98\u20131.94, p &lt; 0.0001). PoV improves CR rates and PFS in patients with NHL, particularly those with relapsed\/refractory disease, but is associated with increased adverse events. Further research is needed on long-term survival outcomes and optimal patient selection. PoV appears to be a promising targeted therapy option for NHL, which warrants further investigation.<\/jats:p>","DOI":"10.3390\/ijms26146836","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:48:22Z","timestamp":1752680902000},"page":"6836","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Efficacy of Polatuzumab Vedotin Targeting CD79B in the Treatment of Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-4789","authenticated-orcid":false,"given":"Samiyah","family":"Alshehri","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11421, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Khan","sequence":"additional","affiliation":[{"name":"Institute of Biotechnology & Genetic Engineering (Health Division), The University of Agriculture Peshawar, Peshawar 25130, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeb Ullah","family":"Khan","sequence":"additional","affiliation":[{"name":"Institute of Biotechnology & Genetic Engineering (Health Division), The University of Agriculture Peshawar, Peshawar 25130, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8533-0855","authenticated-orcid":false,"given":"Ahsanullah","family":"Unar","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u2018L. Vanvitelli\u2019, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.4103\/jfmpc.jfmpc_1037_19","article-title":"Non-Hodgkin\u2019s lymphoma: A review","volume":"9","author":"Singh","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1182\/blood-2022-158830","article-title":"Epidemiology of Non-Hodgkin Lymphoma: Global Patterns of Incidence, Mortality, and Trends","volume":"140","author":"Sedeta","year":"2022","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chu, Y., Liu, Y., Fang, X., Jiang, Y., Ding, M., Ge, X., Yuan, D., Lu, K., Li, P., and Li, Y. (2023). The epidemiological patterns of non-Hodgkin lymphoma: Global estimates of disease burden, risk factors, and temporal trends. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1059914"},{"key":"ref_4","first-page":"226","article-title":"Etiology of non-Hodgkin lymphoma: A review from epidemiologic studies","volume":"2","author":"Luo","year":"2022","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/cas.14933","article-title":"Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review","volume":"112","author":"Yasuda","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1574892818666230117151757","article-title":"The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis","volume":"19","year":"2024","journal-title":"Recent Pat. Anti-Cancer Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/14740338.2020.1802424","article-title":"Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma","volume":"19","author":"Makita","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.2147\/OTT.S219449","article-title":"Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data","volume":"13","author":"Sawalha","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11899-020-00572-7","article-title":"Polatuzumab Vedotin: A New Target for B Cell Malignancies","volume":"15","author":"Choi","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_10","first-page":"256","article-title":"A Comprehensive Review of Polatuzumab vedotin: Mechanisms, Clinical Applications, and Future Prospects","volume":"2","author":"Shanthi","year":"2024","journal-title":"Natl. Board Exam. J. Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/PHMT.S429252","article-title":"Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma","volume":"14","author":"Raqib","year":"2023","journal-title":"Pediatr. Health Med. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/14712598.2020.1777979","article-title":"Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Malecek","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jacobson, C.A. (2020). Antibody-drug Conjugates Change the Standard of Care for Both B- and T-cell Non-Hodgkin Lymphoma. Hematologist, 17.","DOI":"10.1182\/hem.V17.1.10157"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/fon-2020-0675","article-title":"Polatuzumab vedotin, an anti-CD79b antibody\u2013drug conjugate for the treatment of relapsed\/refractory diffuse large B-cell lymphoma","volume":"17","author":"Camus","year":"2021","journal-title":"Future Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2991\/chi.k.210305.001","article-title":"Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma","volume":"3","author":"Assi","year":"2021","journal-title":"Clin. Hematol. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ajh.27341","article-title":"Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"99","author":"Yuen","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Methley, A.M., Campbell, S., Chew-Graham, C., McNally, R., and Cheraghi-Sohi, S. (2014). PICO, PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv. Res., 14.","DOI":"10.1186\/s12913-014-0579-0"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13643-019-1070-0","article-title":"Introducing RAPTOR: RevMan Parsing Tool for Reviewers","volume":"8","author":"Schmidt","year":"2019","journal-title":"Syst. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e19070","DOI":"10.1200\/JCO.2016.34.15_suppl.e19070","article-title":"A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed\/refractory b-cell non-Hodgkin lymphoma: A comparison with non-Japanese DCS4968g study","volume":"34","author":"Hatake","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/cas.14937","article-title":"A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"112","author":"Terui","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"New Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed\/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib\/II Study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/JCO.2021.39.15_suppl.7520","article-title":"Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib\/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed\/refractory (R\/R) B-cell non-Hodgkin\u2019s lymphoma (B-NHL)","volume":"39","author":"Budde","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: Final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V124.21.4457.4457","article-title":"Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma","volume":"124","author":"Morschhauser","year":"2014","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood.V128.22.622.622","article-title":"Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib\/II Study","volume":"128","author":"Phillips","year":"2016","journal-title":"Blood"},{"key":"ref_30","unstructured":"Phillips, T., Brunvand, M., Chen, A.I., Essell, J., Chiappella, A., Diefenbach, C., Cheng, J., Ramies, D., Hirata, J., and Morschhauser, F. (2025, July 08). Safety and Efficacy of Polatuzumab Vedotin+ Obinutuzumab for Relapsed\/Refractory NHL: A Phase 1b\/2 Study. Refractory NHL: A Phase 1b\/2 Study. Available online: https:\/\/ssrn.com\/abstract=3800072."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V126.23.2726.2726","article-title":"Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation","volume":"126","author":"Bartlett","year":"2015","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood.V128.22.1853.1853","article-title":"Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib\/II Study","volume":"128","author":"Tilly","year":"2016","journal-title":"Blood"},{"key":"ref_33","first-page":"2821","article-title":"Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: Results from a randomized phase 2 study","volume":"130","author":"Sehn","year":"2017","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/blood-2018-99-118551","article-title":"Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib\/II Study","volume":"132","author":"Sehn","year":"2018","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Almasri, M., Maher, N., Al Deeban, B., Diop, N.M., Moia, R., and Gaidano, G. (2025). Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104869"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6836\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:10:49Z","timestamp":1760033449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":35,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26146836"],"URL":"https:\/\/doi.org\/10.3390\/ijms26146836","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}